Drugs / MIB-626
MIB-626
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07278492 | Jul 2026 → Mar 2028 expected | Down syndrome | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05040321 | Dec 2021 → Dec 2025 | Alzheimer disease | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05038488 | Oct 2021 → Aug 2023 | COVID-19, acute kidney injury | Metro International Biotech, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04817111 | May 2021 → May 2022 | Friedreich ataxia | Metro International Biotech, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05878119 Comparator | Oct 2023 → Jun 2025 | — | Metro International Biotech, LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIB 626 | “Effects of MIB-626 (β-Nicotinamide Mononucleotide) With and Without A High-Intensity Multi-Dimensional Exercise Training Program on Physical Performance, Muscle Bioenergetics,...” NCT05878119 ↗5“Investigational Product - MIB 626” NCT05878119 ↗ |
| Known as | NMN | “The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of...” NCT05878119 ↗ |
| Known as | β-nicotinamide mononucleotide | “Effects of MIB-626 (β-Nicotinamide Mononucleotide) With and Without A High-Intensity Multi-Dimensional Exercise Training Program on Physical Performance, Muscle Bioenergetics,...” NCT05878119 ↗1“To determine whether MIB-626 (β-nicotinamide mononucleotide), an NAD+ precursor, can safely increase blood NAD+ levels and attenuate acute kidney injury (AKI) and inflammation...” PMID 40746868 ↗ Jun 2025 |
| Action | Inhibit | “inhibits A beta accumulation by reducing its synthesis and increasing its clearance” NCT05040321 ↗ |
| Route | Oral | “By Mouth” NCT04817111 ↗ |